Organon & Co. (OGN)
Health Care
A diversified pharmaceutical company spun from Merck focusing on established branded medicines and medical devices for women's health, infectious disease, and other therapeutic areas.
What Organon & Co. does
Organon & Co. is a healthcare company that develops, manufactures, and commercializes pharmaceutical products and medical devices globally. The company operates across multiple therapeutic areas, generating revenues primarily from established branded pharmaceutical products. Organon was spun off from Merck & Co. to operate as an independent publicly-traded company, maintaining significant global operations across diverse geographies.
Themes: []
Fundamentals
- Price$13.49 as of 2026-07-09 close
- Market cap$3.5B as of 2026-07-10
- 1-year return+36.1% as of 2026-07-09 close
- P/E14.40 as of 2026-07-10
- Net margin+4.0% as of 2026-07-10
- Gross margin+52.8% as of 2026-07-10
- ROE+29.9% as of 2026-07-10
- Debt / equity9.49 as of 2026-07-10
- Revenue growth (YoY)-2.1% as of 2026-07-10
- Revenue CAGR (3y)+0.2% SEC XBRL
- Beta1.52 as of 2026-07-10
Dividend: yield +0.6%; 1-year non-decreasing per-share dividend streak (SEC XBRL).
Key risks (from latest filing)
[]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.